Skip to content
Bored Studies
Recruiting

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

Perspectum · NCT04054310

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Not applicable
Target enrollment
225
US sites recruiting
6
Study start
August 5, 2020
Record last updated
May 19, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.

Being studied: Liver Multi Scan

Conditions: NASH - Nonalcoholic Steatohepatitis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Male and Female subjects aged between 18 and 75 years old
  • Ability to understand and sign a written informed consent forms
  • Patients scheduled to undergo a standard of care diagnostic liver biopsy as follows
  • Percutaneous biopsy with a 16 gauged needle passed into the right lobe
  • Trans-jugular biopsy with an 18 gauged needle passed into the right lobe
  • Patients who are suspected of having NAFLD, who are being considered for treatment, and presenting with two or more of the following risk factors for NASH
  • Elevated liver enzymes (ALT≥40)
  • BMI≥25kG/m\^2
  • Hypertension
  • Type II diabetes
  • Dyslipidameia
  • Low High-density lipoprotein (HDL) (\<40mg/dl in men or \<50mg/dl in women)
  • Hypertriglyceridemia (≥150mg/dl)
  • Hypercholestrolemia (≥200mg/dl)
  • Triglycerides (TG)/HDL>5.0

Exclusion Criteria

  • Prior histopathological diagnosis of NASH
  • Inability to undergo a liver biopsy
  • Prior or planned liver transplantation
  • Patient scheduled to undergo a laparoscopic or wedge liver biopsy or biopsy taken from the left lobe
  • Participation in an investigational new drug (IND) trial in the 30 days before enrolment
  • Other known causes of chronic liver disease based on clinical criteria at the study site such as the following:
  • Alcoholic liver disease
  • Primary biliary cirrhosis
  • Primary sclerosing cholangitis
  • Autoimmune Hepatitis
  • Wilson's disease, hemochromatosis, iron overload
  • Alpha/1/Antitrypsin (A1AT) deficiency
  • HCV, HBV
  • History or diagnosis of cirrhosis and or hepatic decompensation including ascites, hepatic encephalopathy or variceal bleeding
  • Clinically relevant drug or alcohol abuse within 12 months of screening
  • Any contradiction or significant limitation to MRI scanning
  • Claustrophobia preventing MR imaging (requires 15-30 minutes in scanning)
  • Pacemaker or another implanted device
  • Metal in body (such as an aneurysm clip) that might produce artefacts on abdominal MRI or might be adversely impacted by a high magnetic field
  • Inability to lie flat, remain still or briefly hold breath as necessary during MR imaging
  • Medical condition likely to produce significant hypervolemia like congestive heart failure
  • Severe obesity complicating positioning in MR scanner
  • Weight reduction surgery within 3 years
  • Concomitant medical illnesses per investigators discretion (such as HIV infection, recent major surgery, uncontrolled heart disease, concurrent infection or fever of unknown origin, illicit drug use, cancer
  • Clinically significant medical or psychiatric condition considered a high risk participation in an investigational study
  • Failure to give informed consent

Recruiting US locations

  • Arizona Liver Health

    Chandler, AZ 85224

    Site contact: David Rios, MD · drios@azliver.com

  • RUSH University Medical Center

    Chicago, IL 60612

    Site contact: Lelani Fetrow, BSN · Lelani_C_Fetrow@rush.edu

  • Indiana University Health

    Indianapolis, IN 46202

    Site contact: Sreemala Murthy, BSc · srmurthy@iu.edu

  • Icahn School of Medicine at Mount Sinai

    New York, NY 10029

    Site contact: Elianna Sanchez · elianna.sanchez@mssm.edu

  • University of Virginia

    Charlottesville, VA 22908

    Site contact: Cheree Denbee · cjd4a@hscmail.mcc.virginia.edu

  • Virginia Common wealth University

    Richmond, VA 23284

    Site contact: Arun Sanyal, MD · 8048284060 · arun.sanyal@vcuhealth.org

Study contacts (from the official record)

  • Cayden Beyer · 01865655343 · cayden.beyer@perspectum.com
Non-Invasive Quantification of Liver Health in NASH (N-QUAN) (NCT04054310) | Bored Studies